- Conditions
- End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
- Interventions
- MK-2060, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Edgewater, Florida • Miami, Florida • Tampa, Florida + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 821
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease, Anemia
- Interventions
- Roxadustat
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 4
- States / cities
- Riverside, California • Greenbelt, Maryland • Asheville, North Carolina + 1 more
- Conditions
- Renal Insufficiency, Kidney Diseases
- Interventions
- INCB054707
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Tustin, California • Orlando, Florida • San Antonio, Texas
- Conditions
- Renal Disease, End-Stage, Renal Insufficiency, Chronic, Renal Insufficiency, Acute
- Interventions
- Bosutinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- DeLand, Florida • Gainesville, Florida • Miami, Florida + 2 more
- Conditions
- End Stage Liver Disease
- Interventions
- Advance Care Planning Video Decision Support Tool, Verbal Narrative
- Behavioral · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- End-Stage Renal Disease, Hemodialysis Catheter-associated Infection
- Interventions
- catheter lock solution consisting of N-acetylcystein, tigecycline and heparin
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 3
- States / cities
- Houston, Texas
- Conditions
- End Stage Kidney Disease
- Interventions
- Laughter Therapy
- Behavioral
- Lead sponsor
- Satellite Healthcare
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- San Jose, California
- Conditions
- Diabetes Mellitus, Type 2, End Stage Renal Disease, Irritable Bowel Syndrome
- Interventions
- None (Observational)
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 12 Years to 99 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Ovarian Hyperstimulation Syndrome
- Interventions
- Leuprolide acetate
- Drug
- Lead sponsor
- University of Connecticut
- Other
- Eligibility
- 20 Years to 39 Years · Female only
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- End-Stage Renal Disease
- Interventions
- exposure to a high-calcium dialysate bath
- Procedure
- Lead sponsor
- James B. Wetmore, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- End-stage Renal Disease
- Interventions
- tMBSR, Support group
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- End Stage Renal Disease, End Stage Renal Disease on Dialysis, Dialysis Hypotension, Dialysis Induced Hypertension
- Interventions
- Intermittent Non-InvasiveBlood Pressure Monitor
- Device
- Lead sponsor
- The Rogosin Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Peripheral Nerve Tumors
- Interventions
- CPI-0610
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
- Interventions
- AP306 75 mg BID, AP306 125 mg BID, AP306 150 mg BID, AP306 75 mg TID, AP306 100 mg TID, AP306 125 mg TID, Placebo
- Drug
- Lead sponsor
- R1 Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 24
- States / cities
- Huntsville, Alabama • Chula Vista, California • Los Angeles, California + 19 more
- Conditions
- End Stage Renal Disease on Dialysis
- Interventions
- Dialysate Flow Rate
- Device
- Lead sponsor
- Outset Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- San Jose, California
- Conditions
- Antithrombotic
- Interventions
- Enoxaparin, unfractionated heparin (UFH), BMS-986177
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 3
- States / cities
- Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota
- Conditions
- Hyperphosphatemia
- Interventions
- Niacinamide
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- End Stage Renal Disease
- Interventions
- pravastatin
- Drug
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
- Interventions
- [¹⁴C]Etelcalcetide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- End Stage Renal Disease and Kidney Transplantation
- Interventions
- COACH Program
- Behavioral
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Renal Failure Chronic Requiring Hemodialysis
- Interventions
- Soluble Ferric Pyrophosphate (SFP), Standard dialysate
- Drug · Device
- Lead sponsor
- Rockwell Medical Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 38
- States / cities
- Paragould, Arkansas • Pine Bluff, Arkansas • Alhambra, California + 31 more
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- vincristine
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- End Stage Renal Disease
- Interventions
- Drotrecogin alfa activated (Xigris)
- Drug
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
- Interventions
- Angiotensin II, Norepinephrine
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California